The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.

Exclusion Criteria

• •1. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
• •2. Males and females of reproductive potential who are unwilling to use an "effective", protocol specified method(s) of contraception during the study.
• •3. Co-infection with HCV virus, HIV, HEV or HDV or combined with autoimmune liver disease, metabolism-related fatty liver disease, drug-induced liver injury;
• •4. Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging).
• •5. Any history of, or current evidence of, clinical hepatic decompensation (e.g. ascites encephalopathy or variceal hemorrhage) or liver stiffness over 9kpa measured by TE.
• •6. Abnormal hematological and biochemical parameters, including:
• •Hemoglobin \< 10 g/dl Absolute neutrophil count \< 0.75 × 10\^9/L Platelets ≤ 50 × 10\^9/L AST \> 10 × ULN Total Bilirubin \> 2.5 × ULN Albumin \< 3.0 g/dL INR \> 1.5 × ULN (unless stable on anticoagulant regimen) eGFR\<50mL/min
• •7. Received solid organ or bone marrow transplant.
• •8. Malignancy within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc).
• •9. Currently receiving therapy with immunomodulators (e.g. corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion.
• •10. Complicated with uncontrollable cardiovascular and cerebrovascular diseases.
• •11. Subjects on prohibited concomitant medications. Subjects on prohibited medications, otherwise eligible, will need a wash out period of at least 30 days,Known hypersensitivity to study drugs, metabolites, or formulation excipients.
• •12. Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance.
• •13. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.